Prof Andrea Necchi speaks to ecancer about the results from cohort B of the phase 2 KEYNOTE-057 trial where pembrolizumab monotherapy was used to treat patients with high-risk non–muscle-invasive bladder cancer unresponsive to bacillus Calmette–Guérin (BCG)
The results from cohort A showed a clinical complete response rate of 41% at 3 mo and led to the approval of pembro monotherapy for such patients in the United States. Prof Necchi discusses the results from cohort B of the phase 2 KEYNOTE-057 trial.
Pembro showed notable antitumor activity in patients with BCG-unresponsive non-CIS papillary HR NMIBC after ~45 mo of follow-up. Toxicity was manageable and consistent with that in cohort A, with no new safety signals.
Results suggest patients with non-CIS papillary HR NMIBC unresponsive to BCG who declined or were ineligible to undergo RC may also benefit from pembro monotherapy.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
